Saurabh Saha Centessa Pharmaceuticals PLC (CNTA) insider trading activity

Saurabh Saha is Chief Executive Officer of Centessa Pharmaceuticals plc. Currently has a direct ownership of 630,661 shares of CNTA, which is worth approximately $9.88 Million. The most recent transaction as insider was on Oct 23, 2024, when has been sold 2,592 shares (Ordinary Shares) at a price of $15.32 per share, resulting in proceeds of $39,709. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 631K

24.19% 3M change

23.36% 12M change

Total Value Held $9.88 Million

SAURABH SAHA Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 23 2024	SELL Open market or private sale	$39,709 $15.32 p/Share	2,592 Reduced 0.41%	630,661 Ordinary Shares
Oct 22 2024	SELL Open market or private sale	$473,281 $15.67 p/Share	30,203 Reduced 4.55%	633,253 Ordinary Shares
Oct 21 2024	SELL Open market or private sale	$350,839 $15.8 p/Share	22,205 Reduced 3.24%	663,456 Ordinary Shares
Sep 30 2024	SELL Payment of exercise price or tax liability	$572,592 $15.79 p/Share	36,263 Reduced 5.02%	685,661 Ordinary Shares
Sep 20 2024	SELL Open market or private sale	$909,150 $16.53 p/Share	55,000 Reduced 7.08%	721,924 Ordinary Shares
Sep 10 2024	SELL Open market or private sale	$2,891,000 $16.52 p/Share	175,000 Reduced 18.38%	776,924 Ordinary Shares
Sep 10 2024	BUY Exercise of conversion of derivative security	$1,022,000 $5.84 p/Share	175,000 Added 15.53%	951,924 Ordinary Shares
Aug 23 2024	SELL Open market or private sale	$573,807 $12.3 p/Share	46,651 Reduced 5.66%	776,924 Ordinary Shares
Aug 22 2024	SELL Open market or private sale	$6,188 $12.23 p/Share	506 Reduced 0.06%	823,575 Ordinary Shares
Aug 21 2024	SELL Open market or private sale	$45,006 $12.25 p/Share	3,674 Reduced 0.44%	824,081 Ordinary Shares
Aug 20 2024	SELL Open market or private sale	$51,362 $12.32 p/Share	4,169 Reduced 0.5%	827,755 Ordinary Shares
Jun 30 2024	SELL Payment of exercise price or tax liability	$327,454 $9.03 p/Share	36,263 Reduced 4.18%	831,924 Ordinary Shares
Mar 31 2024	SELL Payment of exercise price or tax liability	$409,771 $11.3 p/Share	36,263 Reduced 4.01%	868,187 Ordinary Shares
Feb 01 2024	SELL Payment of exercise price or tax liability	$215,585 $8.19 p/Share	26,323 Reduced 2.83%	904,450 Ordinary Shares
Feb 01 2024	BUY Grant, award, or other acquisition	-	144,200 Added 13.41%	930,773 Ordinary Shares
Dec 31 2023	SELL Payment of exercise price or tax liability	$288,653 $7.96 p/Share	36,263 Reduced 4.41%	786,573 Ordinary Shares
Sep 30 2023	SELL Payment of exercise price or tax liability	$234,621 $6.47 p/Share	36,263 Reduced 4.22%	822,836 Ordinary Shares
Jun 30 2023	SELL Payment of exercise price or tax liability	$213,951 $5.9 p/Share	36,263 Reduced 4.05%	859,099 Ordinary Shares
Mar 31 2023	SELL Payment of exercise price or tax liability	$85,850 $3.9 p/Share	22,013 Reduced 2.4%	895,362 Ordinary Shares
Feb 01 2023	BUY Grant, award, or other acquisition	-	211,400 Added 18.73%	917,375 Ordinary Shares
Dec 31 2022	SELL Payment of exercise price or tax liability	$136,477 $3.1 p/Share	44,025 Reduced 5.87%	705,975 Ordinary Shares
Jul 01 2022	BUY Grant, award, or other acquisition	-	750,000 Added 50.0%	750,000 Ordinary Shares

Also insider at

CLVT

CLARIVATE Plc Technology

Director

Saurabh Saha

Chief Executive Officer

Cheshire, X0

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CNTA shares.

Notify only if

Value

Insider Trading

Get notified when an Centessa Pharmaceuticals PLC insider buys or sells CNTA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Centessa Pharmaceuticals plc

Track Activities on CNTA

Account